As of August 2026, the biggest immediate change is that adapalene 0.1% plus benzoyl peroxide 2.5% is now available over the counter for people aged 12 and older. The other headline—FDA clearance for a Phase 3 denifanstat trial—marks research progress, not an approval or a newly available acne ingredient. For readers choosing treatment now, established acne actives remain the practical focus. The updates mainly affect access, safe product handling, isotretinoin labeling, and what evidence to watch next.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What changed at the drugstore?
- Should benzene concerns change how you use benzoyl peroxide?
- Which ingredients still have the strongest support?
- What changed for isotretinoin?
- What should readers watch next?
What changed at the drugstore?
On May 22, the FDA switched Differin Epiduo acne Gel from prescription to over-the-counter status. The agency's prescription-to-nonprescription switch list identifies the fixed combination as adapalene 0.1% plus benzoyl peroxide 2.5%.
"Fixed combination" means both active ingredients come in one gel at set strengths. The switch therefore expands access to a dual-active treatment without changing the ingredients themselves or establishing a new standard of care. The FDA-approved label gives readers a practical framework:.
- Apply the gel once daily.
- Allow up to three months for results.
- Do not use extra product in an attempt to work faster; overuse can increase irritation.
- Protect the container from light and heat.
Should benzene concerns change how you use benzoyl peroxide?
The available FDA evidence does not support treating every benzoyl peroxide product as unsafe. In 2025 testing, more than 90% of 95 tested products contained undetectable or extremely low benzene levels. Six products had elevated levels and led to retail-level recalls, according to the FDA's benzene testing update.
The useful response is targeted caution: check whether your product and lot were recalled, and discard expired acne products. Storage matters because benzoyl peroxide can degrade into benzene under conditions such as extreme heat. This reinforces the new Epiduo label's heat-protection instruction and makes a hot car or other high-temperature location a poor storage choice.
Which ingredients still have the strongest support?
The current American Academy of dermatology guideline strongly recommends benzoyl peroxide and topical retinoids, the classes represented in the newly OTC combination. It also strongly recommends topical antibiotics and oral doxycycline. Salicylic acid, azelaic acid, and topical clascoterone receive conditional recommendations.
"Conditional" does not mean ineffective; it means the evidence or the balance of benefits and drawbacks supports a less certain recommendation. The guideline also favors combination treatment and limiting systemic antibiotics. Ingredient choice should therefore account for the full regimen, not simply which single active appears strongest on a product label.
What changed for isotretinoin?
On June 17, 2026, the FDA requested updated labels for generic isotretinoin because newer scientific evidence was missing from existing labels. This was a labeling action, not an expansion into routine treatment for mild acne.
Isotretinoin remains intended for severe recalcitrant nodular acne—disease that has resisted other treatment. Its embryo-fetal-risk REMS requirements, an FDA safety program governing access and precautions, also remain in place.
What should readers watch next?
On August 13, the FDA allowed Sagimet's Phase 3 study of denifanstat to proceed. Denifanstat is an investigational oral inhibitor of fatty acid synthase, an enzyme involved in producing fatty acids. The planned U.S. trial will enroll about 800 patients aged 12 and older with moderate-to-severe acne.
It will assess lesion counts and global evaluations after 12 weeks, according to Sagimet's study announcement. Until efficacy and safety results are available and regulators review them, denifanstat is something to watch—not something consumers can select as an approved acne treatment. Readers should also separate acne-oriented cosmetics from approved acne drugs. U.S. law generally does not require FDA preapproval of cosmetic products or ingredients, although marketers remain responsible for safety; packaging that emphasizes "acne-prone skin" is not evidence of drug approval.